When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus.
This webpage is intended to help keep the supply chain field informed of important updates related to the progress and distribution of COVID-19 vaccines. Resources and information will be added and updated often as new developments occur.
AHA COVID-19 Vaccines and Therapeutics
When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus. As the virus surged in 2020, therapeutics were developed to treat those with COVID-19 in outpatient and inpatient settings. This webpage is intended to help keep the field informed of important updates related to the progress and distribution of COVID-19 vaccines, along with in-development therapeutics for patients with COVID-19.
CDC COVID-19 Vaccination Program Interim Playbook
This playbook serves as an interim playbook for state, territorial, tribal and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their jurisdictions.
AHRMM Webinar: COVID 19 Vaccine Supply, Distribution and Handling Overview: An Operation Warp Speed Panel Discussion
Operation Warp Speed Videos
Review the videos provided by HHS and Operation Warp Speed:
Pfizer and BioNTech COVID-19 Vaccine
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
Moderna COVID-19 Vaccine
Moderna COVID‑19 Vaccine is for use for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles. It is an investigational vaccine not licensed for any indication.